Xintela proposes Hans-Joachim Simons as new Board member
Xintela AB (publ) proposes that the company’s shareholders appoint Hans-Joachim Simons as a new member of the Board at the Annual General Meeting on May 6, 2022. Hans-Joachim Simons (born 1962) is the founder and Managing Partner of Bluerock Healthcare Advisors, a dedicated healthcare consultancy firm, and has significant experience in the medtech-, biotech- and […]
Targinta presents new preclinical data on TARG10 at the AACR Annual Meeting
The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), presents new preclinical data on TARG10 at the AACR Annual Meeting (April 8-13) in a poster titled “The integrin α10β1 antibody TARG10 reduces tumor growth and metastasis of triple-negative breast cancer”. Targinta develops first-in-class tumor-targeting antibodies and ADCs against the novel and patent […]
Targinta selects ADC-antibody TARG9 as drug candidate
The oncology company Targinta AB, a wholly owned subsidiary of Xintela AB (publ), today announces the selection of the drug candidate TARG9, a conjugated antibody, or ADC (antibody-drug conjugate), targeting the cancer marker integrin α10β1. The candidate, being developed against triple-negative breast cancer and glioblastoma, now enters preclinical development. TARG9 consists of an integrin α10-antibody […]
Xintela starts clinical study of XSTEM® in knee osteoarthritis
Xintela starts its first-in-human study (Phase I/IIa) with XSTEM® for the treatment of knee osteoarthritis in Australia. XSTEM, which consists of allogeneic (donated) integrin alpha10beta1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Patients with moderate knee osteoarthritis (grade II-III) will receive a single injection of XSTEM into the knee joint. Three different doses […]
Xintela granted 4.8 million SEK from Vinnova
Lund, Sweden, January 18, 2022 – Xintela has been granted SEK 4.8 million from Vinnova within the call “New and improved biological drugs in healthcare”. The grant will support a clinical phase I/IIa study to evaluate Xintela’s stem cell product XSTEM® for the treatment of patients with difficult-to-heal leg ulcers. The project, which will be […]
Xintela and ScanVet Animal Health A/S sign Letter of Intent
Xintela announces today that the company has signed a Letter of Intent with the Danish animal health company ScanVet Animal Health A/S. The parties intend to enter into an agreement to develop, market and sell EQSTEM®, Xintela’s proprietary equine stem cell product, for the treatment of joint diseases including osteoarthritis. Under the Letter of Intent, […]
Update on status and strategy for Xintela and Targinta
Xintela develops stem cell-based treatments with a focus on osteoarthritis and difficult-to-heal leg ulcers and, through its wholly owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers. We are focused on diseases where there is a high medical need and where effective treatments are lacking today. Solid preclinical R&D has laid the foundation for Xintela’s […]
Xintela taking EQSTEM, a stem cell product for horses, towards the market
In a recently completed study in horses, the stem cell product EQSTEM® shows significantly reduced lameness in horses with osteoarthritis (OA) due to joint injury, indicating that this product can reduce joint pain and improve joint function. Xintela is now taking EQSTEM further to the animal health market and will, in dialogue with EMA (European […]
Targinta selects lead drug candidate for triple-negative breast cancer
The preclinical stage oncology biotech company Targinta has selected its first lead drug candidate, TARG10, a therapeutic antibody targeting integrin a10b1. TARG10 has shown strong activity on cancer cells and in preclinical tumor models, with significant inhibitory effects on both growth and metastasis in triple-negative breast cancer models. Xintela, of which Targinta is a wholly […]
Xintela signs with Australian CRO for clinical study
Xintela announces today that the company has signed a contract with GreenLight Clinical, an Australian Contract Research Organisation (CRO) to conduct Xintela’s First-in-Human study using the stem cell product XSTEM. Xintela’s First-in-Human study with the stem cell product XSTEM, a combined phase I/II clinical study on patients with knee osteoarthritis, will be conducted in Australia […]
